Financial Data and Key Metrics Changes - In Q4 2025, total net product and royalty revenue was $263 million, with full-year 2025 total net product and royalty revenue reaching $831 million, exceeding guidance of $750 million-$800 million [5][17] - Non-GAAP R&D and SG&A operating expenses for 2025 were $728 million, below the guidance of $730 million-$760 million [6] - Cash, cash equivalents, and marketable securities totaled $1.95 billion as of December 31, 2025, compared to $1.14 billion as of December 31, 2024 [21] Business Line Data and Key Metrics Changes - Sephience generated $92 million in revenue in Q4 2025 and $111 million since its launch in 2025 [5][12] - The DMD franchise revenue for Q4 2025 was $66 million, with Translarna contributing $39 million and Emflaza $27 million [17] - Evrysdi royalty revenue for full-year 2025 was $244 million [18] Market Data and Key Metrics Changes - Sephience has seen broad uptake across all patient segments, with 946 patients on commercial therapy worldwide as of December 31, 2025 [13] - The company expects to have patients on commercial drug in 20-30 countries by the end of 2026, including Japan and Brazil [8][15] Company Strategy and Development Direction - The main focus for 2026 is to continue the strong momentum of the Sephience launch, with expectations for revenue growth through increased market penetration and geographic expansion [7][8] - The company plans to advance several programs from its innovative R&D platforms, including RNA splicing and ferroptosis inflammation [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential multi-billion dollar global revenue opportunity for Sephience, citing its differentiated profile and broad uptake [8][12] - The company anticipates reaching cash flow break-even in 2026, a significant milestone [7][20] Other Important Information - The company sold the remainder of its Evrysdi royalty for $240 million in December 2025 [19] - The FDA has requested an additional study for Vatiquinone, which the company plans to pursue [39] Q&A Session Summary Question: What is included in the guidance for Sephience sales this year? - The revenue guidance for 2026 is $700 million-$800 million, with the majority expected from Sephience, and contributions from mature products [22][23] Question: How are lost to follow-up patients becoming aware of Sephience? - Many adults previously lost to follow-up are now seeking therapy due to social media awareness and positive patient experiences shared online [30][31] Question: What are the dynamics for Vatiquinone's additional study? - The FDA suggested an open-label or single-arm study with a natural history comparator group, which the company plans to discuss further [39][40] Question: What are the expectations for Sephience's discontinuation rate? - The company is seeing very low discontinuation rates, with high prescription renewal rates, indicating strong early adoption [46][47] Question: How will Sephience's growth in Europe be affected after the free pricing period? - The company anticipates maintaining a strong price based on the clinical data package and ongoing negotiations [51][53]

当地时间2月18日，在接受美国消费者新闻与商业频道（CNBC）采访时，马卡里特别指出了导致美国 在早期药物试验方面落后的三大瓶颈。 这些瓶颈包括医院合同签订以及伦理审查和审批，他称这两项流程"繁琐冗长，导致我们在与那些进展 迅速的国家竞争时处于劣势"。他还认为，提交和获得研究性新药（IND）申请的流程也存在问题，企 业需要提交IND申请才能对产品进行人体试验。 "我们接手的是一个烂摊子，"马卡里直接把"锅"甩锅了拜登政府，声称美国在2024年开展的I期临床试 验方面远远落后于中国。 【文/观察者网 熊超然】美国食品药品管理局（FDA）局长马蒂·马卡里（Marty Makary）日前警告称， 在早期药物研发方面，美国正落后于中国，并呼吁进行改革，以简化新疗法临床试验的启动流程。 如今，中国正迅速转型为全球创新强国。而与此同时，美国决策者一直面临着采取措施促进国内创新的 压力。 来自咨询机构Global Data和金融服务机构摩根士丹利的数据显示，中国目前开展的临床试验数量超过美 国，新药获批数量占全球近三分之一，预计到2040年将占美国FDA批准药物总数的35%。 各地正在建设的生命科学实验室/研发中心面积，按 ...

Core Insights - The company Wanji Genetic disclosed its future plans during the fiscal year 2025 earnings meeting, highlighting significant growth strategies and R&D advancements [1] Performance Strategy - The company plans to increase the size of its pathology sales team by 25% in 2026, focusing on expanding its market share in rare diseases and reproductive health [2] - The biopharmaceutical services will continue to expand multi-omics platform orders [2] - In terms of drug development, the project 007 (head and neck cancer) is expected to advance to Phase III clinical trials, while project 022 (multi-organ cancer) is currently in Phase I [2] - R&D expenditures are projected to potentially double compared to 2025 [2]

智通财经APP获悉，法国制药巨头赛诺菲(SNY.US)即将上任的首席执行官、65 岁的贝伦·加里霍(Belén Garijo)面临一项重大任务：赢得投资者支持，加快这 家法国公司停滞不前的药物研发进程，并在美国总统唐纳德·特朗普执政期间应对疫苗怀疑论。 据接近加里霍的投资者、分析师及其他人士透露，她行事果敢、注重细节且执行力突出，但研发成果却表现参差不齐，其任期内公司股价更出现明显下跌。 值得关注的是，加里霍自2021年起便担任德国默克集团首席执行官。 "赛诺菲首席执行官的变动表明研发转型已经失败或进展过于缓慢，"赛诺菲投资者联合投资公司的投资组合经理马库斯·曼斯(Markus Manns)表示。"贝伦在 赛诺菲的首要任务将是提高研发产出效率。" 曼斯高度评价加里霍成功管理了业务横跨健康与科技领域的默克集团，并特别肯定她去年与美国总统唐纳德·特朗普达成的关键定价协议。不过他同时指 出，在默克集团经历数次研发挫折后，这位首席执行官亟需加速推进创新进程以应对挑战。 "她需要改善自己的研发业绩记录。" 替代哮喘重磅药物度普利尤单抗是重大挑战 开发新药一直是赛诺菲面临的最大问题。度普利尤单抗(Dupixent)占公司 ...

Summary of Edgewise Therapeutics Conference Call Company Overview - **Company**: Edgewise Therapeutics (NasdaqGS:EWTX) - **Event**: 2026 Healthcare Innovation Conference - **Key Speaker**: Behrad Derakhshan, Chief Operating Officer Key Points Industry and Product Focus - Edgewise is focused on developing treatments for hypertrophic cardiomyopathy (HCM) and Becker muscular dystrophy, with significant unmet needs in these areas [5][6] - The company is preparing for a Phase 3 readout in its Becker program with sevasemten, aiming to launch the first drug for Becker patients [5] Clinical Trials and Data - The company is excited about the upcoming Part D data related to obstructive and non-obstructive HCM, emphasizing the rigorous data quality over competitor timelines [16][17] - Changes in screening criteria for clinical trials have been implemented to reduce AFib observations, including extending the look-back period for patient history and enhancing cardiac monitoring [11][12][13] - The company reported no AFib burden during extensive screening, indicating progress in addressing previous concerns [13] Competitive Landscape - Edgewise aims to differentiate its drug by allowing physicians to dose optimize without the need for rigorous echo monitoring, which is a limitation for current treatments [26][27][36] - The company believes there is still room for improvement in the obstructive population, particularly outside of centers of excellence where community physicians manage heart failure [24][25] Future Plans and Regulatory Considerations - Edgewise plans to initiate Phase 3 trials in the fourth quarter of 2026 and is preparing to engage with the FDA regarding registration studies [46][49] - The company is considering the potential for a synergistic use of its drug with current treatments in the obstructive setting, although it may lead to a switch rather than combination therapy [47] Commercial Strategy - Edgewise is building a commercial organization in anticipation of positive data, aiming for a broad label to treat patients diagnosed during adolescence [60][62] - The company is focused on demonstrating the long-term benefits of its drug to justify orphan drug pricing and ensure patient retention [59][60] Other Programs - The company is also advancing EDG-15400, with data expected in the second quarter of 2026, targeting heart failure with preserved ejection fraction (HFpEF) [48][49] - The Grand Canyon study for sevasemten is on track, with a low dropout rate indicating strong patient retention [53][54] Market Positioning - Edgewise is positioning itself to capture a significant market share in HCM and Becker muscular dystrophy by addressing unmet needs and simplifying treatment protocols for physicians [38][60] Conclusion - Edgewise Therapeutics is poised for significant developments in the coming year, with a focus on rigorous data quality, innovative treatment approaches, and a strong commercial strategy to meet the needs of patients with HCM and Becker muscular dystrophy [5][6][60]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 有關自願公告的補充公告 茲提述日期為2026年1月21日的自願公告（「該公告」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供進一步資料說明，防脫泡沫劑產品（「該產品」）為本公司化妝 品品牌KOSHINÉ旗下以KX-826為主要成分的產品之一。本公司謹此澄清，儘 管銷售代理協議為進一步推動本公司化妝品商業化提供了有利機會，但與本 集團的上市業務（即本公司核心產品KX-826及GT20029及其他管線產品的開發 及商業化）（「上市業務」）相比，該化妝品銷售業務目前規模較小，屬輔助性質。 謹此說明，該公告所披露的人民幣100百萬元銷售目標是按累計基準計量的長 期目標，而非預期於短期內達致 ...

I Just Returned From China. We Are Not Winning. 本文作者史蒂文·拉特纳先生是一位特约评论员，曾在奥巴马政府担任财政部长的顾问。 几周前在纽约，我参加了一个讨论美国贸易的晚宴，谈话很快转到了中国问题上。一些资深专家 持截然相反的立场：一些人支持特朗普总统强硬、激进的立场，而另一些人则主张采取不那么对 抗、更为常规的方式。 人力资本是中国成功的关键因素。我接触过无数年轻的中国创业者，他们的活力和才智至少可以 与硅谷的同行相媲美，其中一位中国亿万富翁至今仍睡在办公室里。 尽管特朗普先生大肆宣扬关税，但我们并没有赢得这场贸易战。这个亚洲巨头依然稳居世界最大 出口国之列，其贸易顺差去年更是创下1.2万亿美元的纪录。这一整体增长表明，许多中国商品 仍然在抵达美国，只是经过了中间国。无论是否征收关税，每个人都需要中国商品。 以汽车为例。在我的旅途中，我参观了小米公司，这家智能手机和电子产品制造商五年前才宣布 进军电动汽车行业。在一个几乎空无一人的庞大厂房里，体型庞大的机械装置，看起来像是机器 恐龙，毫不费力地将铝制面板推到位，而汽车则沿着生产线缓缓驶来。大厅里停着一辆黄色跑 ...

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of Ketoprofen Gel Patch, which is intended for pain relief [1] - The product is classified as a Class 3 chemical drug and is indicated for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - The Ketoprofen Gel Patch contains 30mg of Ketoprofen per 10g of gel and is administered topically, with a recommended dosage of one patch twice daily [1] Group 2 - Sales of Ketoprofen Gel Patch in China's major markets are projected to be approximately 49.58 million yuan in 2024 and about 76.44 million yuan in the first half of 2025 [2] - The approval for clinical trials is expected to enhance the company's product pipeline in the orthopedic chronic disease sector, potentially improving its strategic goals and core competitiveness [3] - The company acknowledges the long development cycle and high investment associated with drug research, which may introduce uncertainties regarding the approval and market performance of the product [3]

AnaptysBio Conference Call Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points Company Separation - AnaptysBio is in the process of separating its biopharma operations from its core royalty portfolio, targeting a Q2 2026 separation date [4] - The biopharma business will include three clinical stage programs: - Rosnilimab (completed Phase 2b study in RA, moving to Phase 3) [5] - CD122 program (two studies: one ongoing in celiac disease, one initiating in EOE) [5] - ANB101 (BDCA2 modulator, ongoing Phase 1 trial) [5] - The new biopharma entity will be publicly traded and capitalized adequately to support its clinical trials [5] Royalty Portfolio - The royalty business is anchored on two programs: - Jemperli (royalty from GSK, projected to generate $1.8 billion in revenue this year) [6] - Imsidolimab (outlicensed to Vanda, seeking accelerated approval) [6] - Jemperli's growth rate is expected to remain strong, with significant market share capture anticipated due to its survival data compared to competitors [8][10] - GSK's guidance suggests potential peak sales of over $2.7 billion, with a long runway for growth [14] Clinical Programs - **Rosnilimab**: - End-of-phase 2 meeting with the FDA scheduled to define the size of the Phase 3 program [138] - Focus on securing funding for the Phase 3 program while prioritizing the separation of the companies [146] - **CD122 Program**: - Differentiated mechanism targeting both IL-15 and IL-2 signaling, with applications in celiac disease and eosinophilic esophagitis (EOE) [57][68] - Ongoing studies in celiac disease aim to demonstrate therapeutic benefits for patients with gluten exposure [97][103] - EOE studies will focus on both eosinophil reduction and symptomatic impact, with data expected in 2027 [114] - **ANB101 (BDCA2 Modulator)**: - Competing with a first-generation BDCA2 in Phase 3 trials by Biogen, with AnaptysBio's drug showing a differentiated depletion profile [121][125] Market Potential - Celiac disease has over 2 million patients in the U.S., with approximately 250,000 non-compliant to a gluten-free diet, representing a significant market opportunity [97] - The EOE market is also substantial, with a need for effective treatments beyond existing options [114] Financial Considerations - AnaptysBio has $310 million in cash at the beginning of the year, sufficient to fund operations into 2028 if allocated to the biopharma business [51] - The company has been actively repurchasing stock, indicating confidence in its valuation and future prospects [46] Regulatory Environment - The company is navigating ongoing litigation related to Jemperli, but it does not impact the planned separation of the biopharma business [16][18] Conclusion - AnaptysBio is positioned for significant growth through its clinical programs and the separation of its business units, with a strong focus on capitalizing on its royalty portfolio and advancing its biopharma pipeline. The upcoming data releases and regulatory meetings will be critical in shaping the company's future trajectory.

Core Viewpoint - Cedars Medical (CLDX.US) has announced its key R&D plans for 2026, focusing on multiple clinical trial advancements and platform validation [1] Project Advancement - The Phase III clinical trial for CSU: The main drug Barzol targeting chronic spontaneous urticaria (CSU) is expected to complete patient enrollment by July 2026, which is the most anticipated event by management [2] - Update on the bispecific project CDX622: Data from the multi-dose escalation study is expected to be released in the third quarter of 2026. Results from the subcutaneous single-dose escalation study are also planned for release within 2026. The company aims to initiate mechanism validation studies for severe asthma based on these data [4] - Evaluation of new indications: The company will start assessing the potential for expanding Barzol into new indications such as food allergies and allergic rhinitis [5] Product Development Progress - Announcement of Phase II clinical data: Results from the Phase II studies on nodular prurigo and atopic dermatitis are planned for release in 2026. These studies will be used to determine the dosing regimen for subsequent registration studies [3] Strategic Advancement - Mid to long-term strategic focus: The company is committed to validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the CSU and other disease areas. In terms of commercialization, the plan is to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [6]